Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison-Reference-Cited by-同舟云学术

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison

Published:2016-03-28 Issue:3 Volume:34 Page:300-318
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Dubbelman Anne-Charlotte,Nijenhuis Cynthia M.,Jansen Robert S.,Rosing Hilde,Mizuo Hitoshi,Kawaguchi Shinki,Critchley David,Shumaker Robert,Schellens Jan H. M.,Beijnen Jos H.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-016-0342-y.pdf

Reference24 articles.

1. Tohyama O, Matsui J, Kodama K, Hata-Sugi N, Kimura T, Okamoto K, Minoshima Y, Iwata M, Funahashi Y (2014) Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res 2014:638747. doi: 10.1155/2014/638747

2. Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, Tohyama O, Semba T, Yamaguchi A, Hoshi SS, Mimura F, Haneda T, Fukuda Y, Kamata J, Takahashi K, Matsukura M, Wakabayashi T, Asada M, Nomoto K, Watanabe T, Dezso Z, Yoshimatsu K, Funahashi Y, Tsuruoka A (2014) Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell 6:18. doi: 10.1186/2045-824X-6-18

3. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14(17):5459–5465. doi: 10.1158/1078-0432.CCR-07-5270

4. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122(3):664–671. doi: 10.1002/ijc.23131

5. Okamoto K, Kodama K, Takase K, Sugi NH, Yamamoto Y, Iwata M, Tsuruoka A (2013) Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 340(1):97–103. doi: 10.1016/j.canlet.2013.07.007

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1;Molecular Diversity;2024-08-09

2. The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib;Biomedicine & Pharmacotherapy;2022-01

3. Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis;Current Drug Metabolism;2020-12-29

4. Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria;International Journal of Endocrinology;2020-11-28

5. UDP‐glucuronosyltransferase polymorphisms affect diethylnitrosamine‐induced carcinogenesis in humanized transgenic mice;Cancer Science;2020-09-05